

Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

H E Fuchs, ... , H R Roberts, S V Pizzo

J Clin Invest. 1984;73(6):1696-1703. <https://doi.org/10.1172/JCI111377>.

Research Article

The regulation of human Factor IXa was studied in vitro in human and mouse plasma and in vivo in the mouse. In human plasma, approximately 60% of the 125I-Factor IXa was bound to antithrombin III (ATIII) by 2 h, with no binding to alpha 2-macroglobulin or alpha 1-proteinase inhibitor, as assessed by gel electrophoresis and IgG- antiproteinase inhibitor-Sepharose beads. In the presence of heparin, virtually 100% of the 125I-Factor IXa was bound to ATIII by 1 min. The distribution of 125I-Factor IXa in mouse plasma was similar. The clearance of 125I-Factor IXa was rapid (50% clearance in 2 min) and biphasic and was inhibited by large molar excesses of ATIII-thrombin and alpha 1-proteinase inhibitor-trypsin, but not alpha 2-macro-globulin-trypsin; it was also inhibited by large molar excesses of diisopropylphosphoryl - (DIP-) Factor Xa, DIP-thrombin, and Factor IX, but not by prothrombin or Factor X. The clearance of Factor IX was also rapid (50% clearance in 2.5 min) and was inhibited by a large molar excess of Factor IX, but not by large molar excesses of Factor X, prothrombin, DIP-Factor Xa, or DIP-thrombin. Electrophoresis and IgG- antiproteinase inhibitor-Sepharose bead studies confirmed that by 2 min after injection into the murine circulation, 60% of the 125I-Factor IXa was bound to ATIII. Organ distribution studies with 125I-Factor IXa demonstrated that most of the radioactivity [...]

Find the latest version:

<https://jci.me/111377/pdf>



Regulation of Factor IX_a In Vitro in Human and Mouse Plasma and In Vivo in the Mouse

Role of the Endothelium and the Plasma Proteinase Inhibitors

Herbert E. Fuchs, Helmut G. Trapp, Michael J. Griffith, Harold R. Roberts, and Salvatore V. Pizzo

Departments of Pathology and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710 and Department of Medicine, Pathology, and Biochemistry, Center for Thrombosis and Hemostasis, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

Abstract. The regulation of human Factor IX_a was studied in vitro in human and mouse plasma and in vivo in the mouse. In human plasma, ~60% of the ¹²⁵I-Factor IX_a was bound to antithrombin III (ATIII) by 2 h, with no binding to α₂-macroglobulin or α₁-proteinase inhibitor, as assessed by gel electrophoresis and IgG-antiproteinase inhibitor-Sepharose beads. In the presence of heparin, virtually 100% of the ¹²⁵I-Factor IX_a was bound to ATIII by 1 min. The distribution of ¹²⁵I-Factor IX_a in mouse plasma was similar. The clearance of ¹²⁵I-Factor IX_a was rapid (50% clearance in 2 min) and biphasic and was inhibited by large molar excesses of ATIII-thrombin and α₁-proteinase inhibitor-trypsin, but not α₂-macroglobulin-trypsin; it was also inhibited by large molar excesses of diisopropylphosphoryl- (DIP-) Factor X_a, DIP-thrombin, and Factor IX, but not by prothrombin or Factor X. The clearance of Factor IX was also rapid (50% clearance in 2.5 min) and was inhibited by a large molar excess of Factor IX, but not by large molar excesses of Factor X, prothrombin, DIP-Factor X_a, or DIP-thrombin. Electrophoresis and IgG-antiproteinase inhibitor-Sepharose bead studies confirmed that by 2 min after injection into the murine circulation, 60% of the ¹²⁵I-Factor

IX_a was bound to ATIII. Organ distribution studies with ¹²⁵I-Factor IX_a demonstrated that most of the radioactivity was in the liver. These studies suggest that Factor IX_a binds to at least two classes of binding sites on endothelial cells. One site apparently recognizes both Factors IX and IX_a, but not Factor X, Factor X_a, prothrombin, or thrombin. The other site recognizes thrombin, Factor X_a, and Factor IX_a, but not the zymogen forms of these clotting factors. After this binding, Factor IX_a is bound to ATIII and the complex is cleared from the circulation by hepatocytes.

Introduction

Factor IX is a vitamin K-dependent coagulation protein that can be activated by both the intrinsic and extrinsic pathways (1). Localization of the reactions of the coagulation cascade to the site of vascular injury and the regulation of the activated coagulation factors are important in thrombosis and hemostasis. Recently, Factors IX and IX_a (the activated form of Factor IX) were shown to bind to the same site on endothelial cells in tissue culture (2, 3). Factor X, prothrombin, and thrombin did not bind to this endothelial cell site. Endothelial cell binding may serve to localize clot-promoting activity, as bound Factor IX_a has at least three times the procoagulant activity of Factor IX_a in solution (3).

Relatively little is known about the regulation of Factor IX_a by the plasma proteinase inhibitors, other than antithrombin III (ATIII).¹ Bovine and human Factor IX_a have been shown to react slowly with ATIII, forming a stable 1:1 stoichiometric complex. This reaction is greatly accelerated in the presence of heparin (4-7). The reactions of Factor IX_a with α₂-macroglobulin

Mr. Fuchs is a Predoctoral Fellow, Medical Scientist Training Program (GM-07171). Dr. Trapp was supported by a grant from the Fulbright Commission for educational exchange between the United States and the Federal Republic of Germany.

Received for publication 2 September 1983 and in revised form 17 February 1984.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.
0021-9738/84/06/1696/08

Volume 73, June 1984, 1696-1703

1. Abbreviations used in this paper: ATIII, antithrombin III; α₂M, α₂-macroglobulin; α₁PI, α₁-proteinase inhibitor (α₁-antitrypsin); DIP-, diisopropylphosphoryl-.

(α_2 M) and α_1 -proteinase inhibitor (α_1 PI) have not been described. The present studies were undertaken to examine the regulation of human Factor IX_a in vivo. The distribution of ¹²⁵I-Factor IX_a among the plasma proteinase inhibitors in human plasma in vitro was examined by sodium dodecyl sulfate- (SDS-) polyacrylamide gel electrophoresis and by IgG-antiproteinase inhibitor-Sepharose beads. These results were compared with those obtained from mouse plasma, and the in vivo regulation of Factor IX_a was then studied using our previously described mouse model. We have recently shown that Factor X_a binds to an endothelial cell thrombin-binding site; this binding alters the proteinase inhibitor specificity of Factor X_a such that α_2 M is the primary in vivo inhibitor of Factor X_a, whereas α_1 PI is the primary in vitro inhibitor of Factor X_a (8). In light of these results, the endothelial binding of Factor IX_a and the possible role of this binding in the regulation of Factor IX_a were examined in vivo in our mouse model.

Methods

Reagents. Reagents were obtained as previously described (8).

Proteins. Human Factor IX was purified as previously described (9). Human prothrombin and Factor X were prepared by the method of Miletich et al. (10). Human α -thrombin (specific activity 2,700 U/mg), DIP-thrombin, Factor X_a, and DIP-Factor X_a were prepared as previously described (8, 11, 12). Diisopropylfluorophosphate (20 mM) failed to inhibit Factor IX_a, even after reaction for 6 or 24 h; this is consistent with previous studies (6). Human Factor XI_a was prepared as described by Chung et al. (9) and used to activate Factor IX as previously described (13). Activation was 80–85% complete by 90 min, as determined by SDS-polyacrylamide gel electrophoresis under reducing conditions. α_2 M, ATIII, and α_1 PI were purified from human plasma as previously reported (11, 14, 15). Mouse ATIII was prepared essentially as described for human ATIII (11).

Trypsin was purchased from Worthington Biochemicals (Freehold, NJ) and was 70% active, as determined by active site titration (16). Trypsin complexes of α_2 M, α_1 PI, and ATIII were prepared as previously described (8).

Protein concentration. The concentrations of purified proteins were determined using the extinction coefficients and molecular weights previously reported (6, 10, 11, 17–23).

Protein radiolabeling. Human α_2 M, α_1 PI, and ATIII, and mouse ATIII were radiolabeled with ¹²⁵I by the solid state lactoperoxidase method (24). Radioactivity was measured in a gamma counter (AW14-120; Scientific Products, American Hospital Supply Corp., McGaw Park, IL). Proteins were labeled to specific radioactivities of 1,000–2,000 cpm/ng and assayed for activity. α_2 M was assayed by the method of Ganrot (25). α_1 PI was assayed as described by Dietz et al. by measuring the inhibition of the hydrolysis of α -N-benzoyl-DL-arginine-p-nitroanilide by trypsin (26). ATIII activity was determined as the inhibition of the thrombin-catalyzed hydrolysis of the chromogenic substrate S-2238 (27). In all cases, proteins retained at least 95% activity after radiolabeling. Human Factor IX was radiolabeled with ¹²⁵I using Iodobeads (Pierce Chemical Co., Rockford, IL) in 50 mM Tris-HCl, 0.15 M NaCl, pH 7.4. Typically, 100 μ g Factor IX was incubated with 1.5 mCi ¹²⁵I and two beads at room temperature for 30 min with mixing. Specific radioactivities of 1,000–1,500 cpm/ng were routinely obtained. The radiolabeled Factor IX displayed activity identical to that of the unlabeled

Factor IX, both species being 80–85% activated by Factor XI_a in the presence of Ca⁺⁺ ions, as assessed by SDS-polyacrylamide gel electrophoresis under reducing conditions.

Polyacrylamide gel electrophoresis. SDS-polyacrylamide gel electrophoresis of purified protein samples was performed using 5 and 7.5% acrylamide slab gels as described by Wycoff et al. (28). SDS-polyacrylamide gel electrophoresis of plasma samples was performed on 5% slab gels according to the method of Weber and Osborn (29). 25- μ l plasma samples were denatured in 75 μ l 6% SDS at 95°C for 2 min. After drying, gels containing radioactivity were placed against Kodak XAR-2 film (Cardinal X-ray, Winston-Salem, NC) with an image-intensifying screen overnight at –70°C to prepare autoradiograms. Gel lanes were then sliced into sections 3 mm long in the direction of migration and the radioactivity in each slice was measured in a gamma counter. Protein content was then calculated using the previously determined specific radioactivities of the preparations. Gel profiles were plotted and relative peak areas were obtained by cutting and weighing the peaks.

Reaction of Factor IX_a with purified plasma proteinase inhibitors. Factor IX_a and ¹²⁵I-Factor IX_a were incubated with human α_2 M, α_1 PI, and ATIII, and with mouse ATIII for 2 h at 23° and 37°C in equimolar ratios and at proteinase inhibitor excess. The degree of complex formation was then determined by SDS-polyacrylamide gel electrophoresis, according to the method of Weber and Osborn (29), as described above, to assess the degree of covalent binding of ¹²⁵I-Factor IX_a to each inhibitor and to establish reference markers for the in vitro experiments with mouse and human plasma and for the in vivo clearance studies. In several experiments, the mixture resulting from the incubation of ¹²⁵I-Factor IX_a was subjected to chromatography on Ultrogel ACA22 (LKB Instruments Inc., Gaithersburg, MD) before electrophoresis.

IgG-antiproteinase inhibitor-Sepharose beads. The IgG fraction of goat antihuman α_2 M, α_1 PI, or ATIII was coupled to CNBr-activated Sepharose 4B CL as previously described (8). The beads were characterized by incubating 50 μ l of the resultant IgG-Sepharose preparations with 1–500 μ g ¹²⁵I-labeled human α_2 M, α_1 PI, and ATIII, and mouse ATIII, or with the corresponding ¹²⁵I-proteinase inhibitor-trypsin complex in 500 μ l of 50 mM Tris-HCl, 0.15 M NaCl, 60 mg/ml bovine serum albumin, pH 7.40, at 37°C for 2 h with constant mixing in a series of saturation curves. The tubes were then centrifuged in an Eppendorf microcentrifuge. The supernatants were removed and the beads were washed three times with cold Tris buffer (1 ml each). The bottoms of the tubes were cut off and the radioactivity content in beads, supernatants, and washes was determined. Under the conditions chosen for the experiments described below, 80–90% of the applied ¹²⁵I-labeled proteinase inhibitors bound to the corresponding IgG-Sepharose, with ~1.5% non-specific binding, as determined by incubating the noncorresponding inhibitors with a given IgG-Sepharose sample. The binding of the proteinase inhibitors to their corresponding IgG-Sepharoses was virtually unaffected by the formation of trypsin complexes before incubation with the beads. ¹²⁵I-Factor IX_a was also incubated with the IgG-Sepharoses; maximal binding of this ligand to any of the IgG-Sepharose preparations was 12%.

Mouse plasma. Mouse plasma for in vitro studies was obtained by incising anesthetized mice in the midline and cannulating the inferior vena cava. Blood was drawn into syringes containing 0.1 vol 3.8% sodium citrate and centrifuged immediately. The plasma was drawn off and used in experiments within 1 h of bleeding.

Plasma studies in vitro. Citrated human or mouse plasma (250 μ l) was incubated with 1 μ g ¹²⁵I-Factor IX_a at 37°C. Samples (25 μ l) were removed at various times and either incubated with IgG-Sepharose beads in 500 μ l of 50 mM Tris-HCl, 0.15 M NaCl, 60 mg/ml albumin, pH

7.40, as described above, or denatured immediately for SDS-gel electrophoresis.

Plasma elimination studies. Plasma elimination studies of ^{125}I -Factor IX and ^{125}I -Factor IX_a (0.5 to 1 μg) alone or in the presence of large molar excesses of unlabeled proteins were performed in CD-1 female mice, as previously described (8). To examine the distribution of Factor IX_a between the plasma and the cellular elements of blood, ^{125}I -Factor IX_a was injected and 800 μl of blood was collected after 5 min into 0.1 vol 3.8% sodium citrate. The sampled blood was centrifuged at 10,000 g for 10 min at 4°C to pellet the cellular elements and the supernatant plasma was removed with a pipette. The cellular pellet was washed three times with 1 ml cold 0.05 M Hepes, 0.15 M NaCl, pH 7.40, and the radioactivity content of the plasma, washes, and the cellular pellet was determined. In some plasma elimination studies, duplicate samples were taken at each time point. One sample was counted in a gamma counter, the other was drawn into 0.1 vol 3.8% sodium citrate and centrifuged immediately at 4°C. The plasma was then denatured immediately for SDS-gel electrophoresis. In general, studies were performed at least four times.

Tissue distribution studies. Organ distribution studies were performed as previously described after injection of 5 μg of ^{125}I -ligand (30).

Results

Reaction of Factor IX_a with purified plasma proteinase inhibitors.

There was no evidence of complex formation of either Factor IX_a or ^{125}I -Factor IX_a with α₂M or α₁PI after 2 h at 23°C or 37°C, as assessed by SDS-polyacrylamide gel electrophoresis (data not shown). With human or mouse ATIII, ~50% of the Factor IX_a or ^{125}I -Factor IX_a had been converted to the ATIII complex by 2 h at 23°C or 37°C. In the presence of heparin (10 U/ml), the conversion of Factor IX_a or ^{125}I -Factor IX_a to the complex with either human or mouse ATIII was virtually 100% complete by 1 min at either 23° or 37°C (data not shown).

In vitro distribution of Factor IX_a among the proteinase inhibitors in human and mouse plasma. The time course of inactivation of ^{125}I -Factor IX_a in human and mouse plasma was studied using SDS-polyacrylamide gel electrophoresis. The results obtained with human and mouse plasma were virtually identical; the time course of inactivation of ^{125}I -Factor IX_a in mouse plasma is shown in Fig. 1, lanes a-i, for comparison with the in vivo results described below. Complexes of α₂M and proteinase would be seen at the top of the gel lanes if they were present. The results for both human and mouse plasma are summarized in Table I. Approximately 60% of the ^{125}I -Factor IX_a was bound to ATIII by 2 h, with no binding to α₂M in either human or mouse plasma. From these data, based on the use of 1 μg of ^{125}I -Factor IX_a and 250 μl of plasma, it is possible to calculate the rate of inhibition of Factor IX_a by ATIII. Both human and mouse ATIII inhibited ~0.02 μg of human Factor IX_a/ml plasma per min. In the presence of heparin (10 U/ml), virtually 100% of the ^{125}I -Factor IX_a was bound to ATIII by 1 min (Table I).

IgG-antiproteinase inhibitor-Sepharose bead studies. Samples of human plasma, after 2 h of incubation with ^{125}I -Factor IX_a, were mixed with goat IgG-antihuman α₂M, α₁PI, or ATIII co-




Figure 1. In vitro and in vivo distribution of ^{125}I -Factor IX_a in mouse plasma. SDS-polyacrylamide gel electrophoresis of 1 μg ^{125}I -Factor IX_a incubated with: (a-i) 250 μl citrated mouse plasma for various times (a, 0; b, 1; c, 5; d, 10; e, 20; f, 30; g, 60; h, 90; i, 120 min) or (j) injected into a mouse, with plasma collected after 2 min.

valently linked to Sepharose. The experiment was repeated in the presence of heparin (10 U/ml) after 1 min of incubation of ^{125}I -Factor IX_a with the heparinized plasma (Table II). The experiments were repeated with mouse plasma in the presence and absence of heparin (10 U/ml) using only the anti-ATIII-Sepharose beads. The results are essentially identical to those obtained with human plasma and are shown in Table II. These results show that ATIII is the primary inhibitor of Factor IX_a in vitro in human and mouse plasma, although in the absence of heparin the reaction is slow.

Plasma elimination of Factor IX. The clearance curve of ^{125}I -Factor IX is biphasic (Fig. 2 A), with an initial rapid dis-

Table I. In Vitro Distribution of ^{125}I -Factor IX_a in Human and Mouse Plasma Determined by SDS-Polyacrylamide Gel Electrophoresis

Plasma	Incubation conditions	Proteinase inhibitor-bound Factor IX _a (% Factor IX _a in peak)		
		α ₂ M	ATIII	Free Factor IX _a
Human	2 h no heparin	0	62.8	37.2
	1 min + heparin	0	99.5	0.5
Mouse	2 h no heparin	0	60.5	39.5
	1 min + heparin	0	99.0	1.0

Table II. *In Vitro* Distribution of ^{125}I -Factor IX_a in Human and Mouse Plasma Determined by Adsorption of IgG-Sepharose

Plasma	Incubation conditions	Antiserum to inhibitor (% total binding)			Free Factor IX _a (% total)
		$\alpha_2\text{M}$	$\alpha_1\text{PI}$	ATIII	
Human	2 h no heparin	0	0	64.3	35.7
	1 min + heparin	0	0	98.7	1.3
Mouse	2 h no heparin	—	—	61.4	—
	1 min + heparin	—	—	98.1	—

appearance of protein followed by a slow phase of longer duration. Blood from one experimental animal sampled 10 min after injection of ^{125}I -Factor IX was reinjected into a second animal. The reinjected blood cleared identically (Fig. 2 A), thus mediating against a rapidly clearing subpopulation of modified Factor IX or contaminants. A 2,000-fold molar excess of unlabeled Factor IX inhibited the clearance of labeled Factor IX, prolonging the half-life of ^{125}I -Factor IX from 2 to 10 min (Fig. 2). These results suggest that Factor IX is rapidly cleared from the circulation, probably owing to endothelial cell binding as previously described *in vitro* (3). The slow late phase of clearance probably results from equilibration of the injected Factor IX with the murine Factor IX pool. To establish the specificity of this clearance process, competition experiments were performed

with Factor X and prothrombin. Even at a 2,000-fold molar excess, neither species inhibited the clearance of ^{125}I -Factor IX (Fig. 2 A). Competition experiments were also performed with DIP-Factor X_a and DIP-thrombin, with no inhibition of the clearance of ^{125}I -Factor IX, even at 2,000-fold molar excesses (Fig. 2 B).

Plasma elimination of Factor IX_a. The clearance of ^{125}I -Factor IX_a was rapid and biphasic (Fig. 3 A). To further characterize the clearance of Factor IX_a, competition experiments were performed with unlabeled Factor IX, Factor X, prothrombin, DIP-Factor X_a, and DIP-thrombin (Fig. 3, A and B). Among the zymogens, only Factor IX inhibited the clearance of ^{125}I -Factor IX_a, indicating that Factor IX and Factor IX_a are cleared by a site that recognizes both the zymogen and the activated species. Both DIP-thrombin and DIP-Factor X_a also inhibited the clearance of ^{125}I -Factor IX_a at 2,000-fold molar excess. These results indicate that Factor IX_a binds to the high affinity endothelial cell thrombin-binding sites described by Lollar and Owen (31), which we have recently shown also bind Factor X_a (8).

In order to study directly the clearance of inactivated Factor IX_a, an attempt was made to prepare DIP-Factor IX_a. Previous studies by Davie and colleagues (6) suggested that human Factor IX_a is not inhibited by diisopropylfluorophosphate. In the present study, Factor IX_a was treated with this reagent at a concentration of 20 mM for either 6 or 24 h. There was no loss of Factor IX_a activity as compared with a control preparation of Factor IX_a incubated under similar conditions in the absence of the inhibitor. This contrasts markedly with trypsin, which in 15 min is completely inactivated at a 1 mM concentration of diisopropylfluorophosphate. Thrombin is also rapidly inhibited under these reaction conditions (31). Therefore, it was impossible to study the clearance of DIP-Factor IX_a.

The possibility that the cellular elements of blood are in-




Figure 2. Clearance from the circulation of intravenously injected Factor IX. ^{125}I -labeled protein (0.5–1.0 μg) was injected into mice and blood samples were collected at intervals. (A) ^{125}I -Factor IX (●). Reinjection study of ^{125}I -Factor IX (○). The clearance of ^{125}I -Factor IX in the presence of 2,000-fold molar excesses of Factor IX (▲), Factor X (△), and prothrombin (□). (B) The clearance of ^{125}I -Factor IX in the presence of 2,000-fold molar excesses of DIP-Factor X_a (●) or DIP-thrombin (○). The clearance of Factor IX alone is shown as a dashed line for comparison.




Figure 3. Clearance from the circulation of intravenously injected Factor IX_a. Clearance studies as described in Fig. 2. (A) ¹²⁵I-Factor IX_a (●). The clearance of ¹²⁵I-Factor IX_a in the presence of 2,000-fold molar excesses of Factor IX (▲), Factor X (△), or prothrombin (□). (B) The clearance of ¹²⁵I-Factor IX_a in the presence of 2,000-fold molar excesses of DIP-Factor IX_a (●) or DIP-thrombin (○). The clearance of Factor IX_a alone is shown as a dashed line for comparison.

involved in the catabolism of Factor IX_a was investigated by injecting ¹²⁵I-Factor IX_a into a mouse, collecting blood into 0.1 vol sodium citrate, separating the plasma and cellular elements as described in Methods, and determining the radioactivity content of each. The cellular pellet contained 0.4% of the recovered radioactivity; the remaining 99.6% was in the plasma.

The role of the plasma proteinase inhibitors in the catabolism of Factor IX_a was investigated using trypsin complexes of α₂M and α₁PI, and ATIII-thrombin. The clearance pathways for proteinase complexes of these inhibitors have been characterized in mouse (11, 14, 15). At a 2,000-fold molar excess, α₂M-trypsin failed to inhibit the clearance of Factor IX_a (Fig. 4). At 2,000-fold molar excesses, both ATIII-thrombin and α₁PI-trypsin inhibited the clearance of ¹²⁵I-Factor IX_a, with α₁PI-trypsin providing somewhat poorer competition. These results are consistent with the clearance of proteinase complexes of ATIII and α₁PI by the same hepatocyte receptor (15).




Figure 4. Clearance from the circulation of intravenously injected Factor IX_a. Clearance studies are as described in Fig. 2. The clearance of ¹²⁵I-Factor IX_a in the presence of 2,000-fold molar excesses of ATIII-thrombin (●), α₁PI-trypsin (○), and α₂M-trypsin (▲). The clearance of ¹²⁵I-Factor IX_a alone is shown as a dashed line for comparison.

To characterize further the proteinase inhibitor-dependent phase of Factor IX_a clearance, complexes of human ATIII-¹²⁵I-Factor IX_a were prepared and used in clearance studies (Fig. 5). The clearance of ATIII-¹²⁵I-Factor IX_a was extremely rapid (50% clearance in 1.5 min). The clearance of ATIII-¹²⁵I-Factor IX_a was inhibited by 2,000-fold molar excesses of ATIII-thrombin and to a slightly lesser degree by α₁PI-trypsin.

Organ distribution of ¹²⁵I-Factor IX and ¹²⁵I-Factor IX_a. Radiolabeled Factor IX or Factor IX_a was injected intravenously. The distributions of radioactivity at 2 and 20 min are shown in Table III. Both species are found predominantly in the liver.

In vivo distribution of ¹²⁵I-Factor IX_a among the plasma proteinase inhibitors. A plasma sample obtained 2 min after the injection of ¹²⁵I-Factor IX_a was subjected to SDS-polyacrylamide gel electrophoresis (Fig. 1, lane j). By this time 50% of the ligand had left the plasma compartment. The relative amounts of ¹²⁵I-Factor IX_a in the various species are shown in




Figure 5. Clearance from the circulation of intravenously injected ATIII-¹²⁵I-Factor IX_a complexes. Clearance studies are as described in Fig. 2. Clearance of ATIII-¹²⁵I-Factor IX_a (●) in the presence of 2,000-fold molar excesses of ATIII-thrombin (○) and α₁PI-trypsin (▲).

Table III. Organ Distribution of ¹²⁵I-Factor IX or ¹²⁵I-Factor IX_a

	% Recovered dose		
	Factor IX	Factor IX _a	
	2 min	2 min	20 min
Heart	0.7	0.6	0.5
Lung	2.0	2.4	1.9
Spleen	5.3	4.0	4.2
Kidneys	5.5	7.7	10.4
Liver	86.0	85.0	83.0

Table IV. A duplicate plasma sample was incubated with IgG-anti-ATIII-Sepharose beads, and the distribution of ¹²⁵I-Factor IX_a was calculated (Table IV). These results demonstrate that nearly 60% of the recovered ¹²⁵I-Factor IX_a is in the form of the complex with ATIII after 2 min, yielding a calculated rate of inhibition of ~0.1 μg human Factor IX_a/ml plasma per min, assuming a plasma volume of ~1.5 ml in the mouse (14).

Discussion

These studies were undertaken to elucidate the catabolism of Factor IX_a. Relatively little is known about the reaction of Factor IX_a with the plasma proteinase inhibitors, except for ATIII. Factor IX_a reacts slowly with ATIII in the absence of heparin (4-7). The reactions of Factor IX_a with α₂M and α₁PI have not been described. These results were confirmed using Factor IX_a and the purified plasma proteinase inhibitors. The inhibition of Factor IX_a by ATIII was slow in the absence of heparin. In the presence of heparin (10 U/ml) the reaction was essentially 100% complete by 1 min. There was no evidence of complex formation with either α₁PI or α₂M, even after 2 h incubation with Factor IX_a.

In vitro studies with human and mouse plasma confirmed the results obtained with the purified inhibitors, as ATIII was shown to inhibit >60% of the Factor IX_a by 2 h, with no evidence of Factor IX_a bound to either α₂M or α₁PI. These results also rule out the possibility of proteinase transfer to α₂M, as described

Table IV. In Vivo Distribution of ¹²⁵I-Factor IX_a Among the Plasma Proteinase Inhibitors by SDS-Polyacrylamide Gel Electrophoresis and IgG Sepharose

	% Total Factor IX _a			
	α ₂ M	α ₁ PI	ATIII	Free Factor IX _a
SDS-polyacrylamide gel	0	—	57.1	42.9
IgG Sepharose	—	—	59.6	40.4

for porcine trypsin with α₁PI and α₂M (32). These results indicate that ATIII is the primary inhibitor of ATIII in vitro in human and mouse plasma. Clearance studies with mice were then undertaken to determine if this result also holds in vivo. We have recently shown that endothelial cell binding alters the proteinase inhibitor specificity of Factor X_a, such that α₂M becomes the primary in vivo inhibitor of Factor X_a, whereas α₁PI is the primary in vitro inhibitor of Factor X_a. Recently, it has been shown in vitro that Factor IX binds to a specific site on endothelial cells and that this site can also bind Factor IX_a, but not prothrombin, thrombin, or Factor X (2, 3). The clearance of ¹²⁵I-Factor IX was rapid and was inhibited by a large molar excess of unlabeled Factor IX, but not by large molar excesses of prothrombin, Factor X, DIP-thrombin, or DIP-Factor X_a. We attempted to prepare DIP-Factor IX_a for study, but were unable to obtain this derivative even under extreme reaction conditions. This observation agrees with previous studies by Davie and colleagues (6).

The results of the present study are consistent with the in vitro endothelial cell binding experiments described above. The clearance of ¹²⁵I-Factor IX_a was also rapid and was inhibited by a large molar excess of unlabeled Factor IX, but not by large molar excesses of prothrombin and Factor X. The clearance of ¹²⁵I-Factor IX_a was also inhibited by large molar excesses of DIP-thrombin and DIP-Factor X_a, indicating that Factor IX_a also binds to endothelial cell thrombin binding sites described by Lollar and Owen (31), which we have recently shown also bind Factor X_a (8). This result contrasts with the in vitro endothelial cell binding studies described above, where thrombin did not inhibit the binding of Factor IX_a to endothelial cells. This discrepancy may be due to cell damage or to loss of the binding site during preparation of the cells for cell culture. These results, together with the clearance and competition studies with Factor IX, suggest that there is at least one class of endothelial cell binding sites that recognizes the activated species Factors IX_a and X_a and thrombin, but not the zymogen forms, Factor IX, Factor X, and prothrombin. The nature of the in vivo thrombin binding site is unclear. One class of endothelial cell thrombin site is thrombomodulin. The binding of thrombin to thrombomodulin alters the substrate specificity of thrombin, since the cleavage of fibrinogen and Factor V by thrombin bound to thrombomodulin is drastically reduced (33). However, thrombin bound to thrombomodulin activates protein C at least 100-fold faster than does free thrombin (34). From the data obtained to date (2, 3, 8, 33), there is no evidence that thrombomodulin is the binding site for Factor X_a or Factor IX_a, and it seems from the present work that there are at least two classes of Factor IX_a binding sites. From all these observations it seems likely that there are several classes of endothelial binding sites that bind the vitamin K-dependent proteinases.

The possibility that the cellular elements of blood may be involved in the catabolism of Factor IX_a was investigated by separating the plasma and cellular elements from an in vivo blood sample by centrifugation. The plasma fraction contained 99.6% of the recovered radioactivity, indicating that the cellular

elements of blood, such as platelets and leukocytes, are not involved in the regulation of Factor IX_a.

The role of the plasma proteinase inhibitors in the catabolism of Factor IX_a was examined by competition experiments with large molar excesses of unlabeled α_2 M-trypsin, α_1 PI-trypsin, and ATIII-thrombin complexes. The clearance pathways for proteinase complexes of these proteinase inhibitors have been well studied (11, 14, 15), and it has been found that proteinase complexes of ATIII and α_1 PI are cleared by the same receptor on hepatocytes (15). The clearance of 125 I-Factor IX_a was not inhibited by a large molar excess of α_2 M-trypsin, indicating that α_2 M is not involved in the *in vivo* catabolism of Factor IX_a.

ATIII-thrombin and α_1 PI-trypsin inhibited the clearance of 125 I-Factor IX_a, with α_1 PI-trypsin providing somewhat poorer competition. These results are consistent with the clearance of α_1 PI- and ATIII-proteinase complexes by the same hepatocyte receptor, with α_1 PI-trypsin complexes clearing with a longer half-time of elimination, as previously described (15). To characterize further the proteinase inhibitor-dependent phase of Factor IX_a catabolism, clearance studies were performed with ATIII- 125 I-Factor IX_a complexes. The clearance of these complexes was extremely rapid (50% clearance in 1.5 min) and was inhibited by large molar excesses of unlabeled ATIII-thrombin, and to a slightly lesser extent by α_1 PI-trypsin, consistent with the results described above.

Organ distribution studies with 125 I-Factor IX or 125 I-Factor IX_a indicate that most of the recovered counts are in the liver, an organ rich in endothelium, and also the site of binding of ATIII-proteinase complexes.

The distribution of Factor IX_a among the plasma proteinase inhibitors *in vivo* was also examined by SDS-polyacrylamide gel electrophoresis and IgG-antiproteinase inhibitor-Sepharose beads. These experiments demonstrate that nearly 60% of the recovered 125 I-Factor IX_a was in the form of the ATIII complex after 2 min, whereas the *in vitro* inhibition of Factor IX_a is considerably slower. From the data obtained *in vitro* in mouse and human plasma and *in vivo* in the mouse, we calculated the rate of inhibition of Factor IX_a by ATIII. There was at least a fivefold increase in the rate of inhibition of human Factor IX_a *in vivo*.

Previous studies by Stern et al. (3) demonstrated that human Factor IX_a binds to bovine endothelium and has at least three times the procoagulant activity of Factor IX_a in solution. These investigators did not examine the effect of Factor IX_a binding on the reaction of Factor IX_a with ATIII. It is interesting that the present data suggest a fivefold increase in binding of human Factor IX_a to murine ATIII in the presence of murine endothelium. While such data may not be directly comparable, both coagulant activity and binding to ATIII involve similar active site-substrate interactions, with ATIII functioning as a suicide substrate. It appears, therefore, that there is considerable conservation of functional and binding properties of the vitamin K-dependent proteinases, despite the different species employed for study. These data are consistent with previous studies from this laboratory that examined the reaction of human α -thrombin

with both human and murine ATIII (11, 15), as well as with studies that compared the reactivity of human Factor X_a to that of ATIII from both species (8).

In summary, our data suggest that there are at least two classes of Factor IX binding sites *in vivo*. One class of sites apparently binds both Factor IX and Factor IX_a, while the other class binds the activated forms of prothrombin, Factor X, and Factor IX.

Acknowledgment

This work was supported by grants from the National Heart, Lung, and Blood Institute (HL 24066, HL 06350, and HL 07255).

References

1. Jackson, C. M., and Y. Nemerson. 1980. Blood coagulation. *Annu. Rev. Biochem.* 49:765-811.
2. Heimark, R. L., and S. M. Schwartz. 1983. Binding of coagulation factors IX and X to the endothelial cell surface. *Biochem. Biophys. Res. Commun.* 111:723-731.
3. Stern, D. M., M. Drillings, H. L. Nossel, A. Hurlet-Jensen, K. S. LaGamma, and J. Owen. 1983. Binding of factors IX and IX_a to cultured vascular endothelial cells. *Proc. Natl. Acad. Sci. USA.* 80:4119-4123.
4. Rosenberg, J. S., P. W. McKenna, and R. D. Rosenberg. 1975. Inhibition of human factor IX_a by human antithrombin. *J. Biol. Chem.* 250:8883-8888.
5. Kurachi, K., K. Fujikawa, G. Schmer, and E. W. Davie. 1976. Inhibition of bovine factor IX_a and factor X_a by antithrombin III. *Biochemistry.* 15:373-377.
6. Di Scipio, R. G., K. Kurachi, and E. W. Davie. 1978. Activation of human Factor IX (Christmas Factor). *J. Clin. Invest.* 61:1528-1538.
7. Bjork, I., C. M. Jackson, H. Jornvall, K. K. Lavine, K. Nordling, and W. J. Salsgiver. 1982. The active site of antithrombin. *J. Biol. Chem.* 257:2406-2411.
8. Fuchs, H. E., and S. V. Pizzo. 1983. The regulation of Factor X_a *in vitro* in human and mouse plasma and *in vivo* in mouse. The role of the endothelium and the plasma proteinase inhibitors. *J. Clin. Invest.* 72:2041-2049.
9. Chung, K. S., D. A. Madar, J. C. Goldsmith, H. S. Kingdon, and H. R. Roberts. 1978. Purification and characterization of an abnormal Factor IX (Christmas Factor) molecule. Factor IX Chapel Hill. *J. Clin. Invest.* 62:1078-1085.
10. Miletich, J. P., G. J. Broze, and P. W. Majerus. 1980. The synthesis of sulfated dextran beads for isolation of human coagulation factors II, IX, and X. *Anal. Biochem.* 105:304-310.
11. Shifman, M. A., and S. V. Pizzo. 1982. The *in vivo* metabolism of antithrombin III and antithrombin III complexes. *J. Biol. Chem.* 257:3243-3248.
12. Thompson, A. R. 1976. High affinity binding of human and bovine thrombins to *p*-chlorobenzylamido- ϵ -aminocaproylagarose. *Biochim. Biophys. Acta.* 422:200-209.
13. Braunstein, K. M., C. M. Noyes, M. J. Griffith, R. L. Lundblad, and H. R. Roberts. 1981. Characterization of the defect in activation of Factor IX_{Chapel Hill} by human Factor XI_a. *J. Clin. Invest.* 68:1420-1426.
14. Imber, M. J., and S. V. Pizzo. 1981. Clearance and binding of two electrophoretic "fast" forms of human α_2 -macroglobulin. *J. Biol. Chem.* 256:8134-8139.

15. Fuchs, H. E., M. A. Shifman, and S. V. Pizzo. 1982. The *in vivo* catabolism of α_1 -proteinase inhibitor-trypsin, antithrombin III-thrombin, and α_2 -macroglobulin-methylamine. *Biochim. Biophys. Acta.* 716:151-157.
16. Chase, T., and E. Shaw. 1967. *p*-nitrophenyl-*p'*-guanidobenzoate HCl: a new active site titrant for trypsin. *Biochem. Biophys. Res. Commun.* 29:508-514.
17. Fenton, J. W. II, B. H. Landis, D. A. Walz, and J. S. Finlayson. 1972. Human thrombins. In *Chemistry and Biology of Thrombin*. R. L. Lundblad, J. W. Fenton II, and K. Mann, editors. Ann Arbor Science, Ann Arbor. 43-70.
18. Di Scipio, R. G., M. A. Hermodson, and E. W. Davie. 1977. Activation of human factor X (Stuart factor) by a protease from Russell's viper venom. *Biochemistry.* 16:5253-5260.
19. Hall, P. K., and R. C. Roberts. 1978. Physical and chemical properties of human α_2 -macroglobulin. *Biochem. J.* 171:27-28.
20. Gonias, S. L., A. E. Balber, W. J. Hubbard, and S. V. Pizzo. 1983. Ligand binding, conformational change and plasma elimination of human, mouse, and rat α -macroglobulin proteinase inhibitors. *Biochem. J.* 209:99-105.
21. Kurachi, K., G. Schmer, M. A. Hermodson, D. C. Teller, and E. W. Davie. 1976. Characterization of human, bovine, and horse antithrombin III. *Biochemistry.* 15:368-373.
22. Pannell, R., D. Johnson, and J. Travis. 1974. Isolation and properties of human α -1-proteinase inhibitor. *Biochemistry* 13:5439-5445.
23. Takahara, H., and H. Sinohara. 1982. Mouse plasma trypsin inhibitors. Isolation and characterization of α 1-antitrypsin and contrapsin, a novel trypsin inhibitor. *J. Biol. Chem.* 257:2438-2466.
24. David, G. S., and R. A. Reisfeld. 1974. Protein iodination with solid state lactoperoxidase. *Biochemistry.* 13:1014-1021.
25. Ganrot, P. O. 1966. Determination of α_2 -macroglobulin as trypsin protein esterase. *Clin. Chim. Acta.* 14:493-501.
26. Dietz, A. A., H. M. Rubinstein, and L. V. Hodges. 1974. Measurement of alpha₁-antitrypsin in serum by immunodiffusion and by enzymatic assay. *Clin. Chem.* 20:396-399.
27. Abildgaard, U., M. Lie, and O. R. Odegaard. 1977. Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and chromozym TH). *Thromb. Res.* 11:549-553.
28. Wyckoff, M., D. Rodbard, and A. Chrambach. 1977. Polyacrylamide gel electrophoresis in sodium dodecyl sulfate-containing buffers using multiphasic buffer systems: properties of the stack, valid R_f measurement, and optimized procedure. *Anal. Biochem.* 78:459-482.
29. Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* 244:4406-4412.
30. Gonias, S. L., M. Einarsson, and S. V. Pizzo. 1982. Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. *J. Clin. Invest.* 70:412-423.
31. Lollar, P., and W. G. Owen. 1980. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. *J. Clin. Invest.* 66:1222-1230.
32. Beatty, K., J. Travis, and J. Bieth. 1982. The effect of α_2 -macroglobulin on the interaction of α 1-proteinase inhibitor with porcine trypsin. *Biochim. Biophys. Acta.* 704:221-226.
33. Esmon, C. T., N. L. Esmon, and K. W. Harris. 1982. Complex formation between thrombin and thrombomodulin inhibits both thrombin catalyzed fibrin formation and factor V activation. *J. Biol. Chem.* 257:7944-7947.
34. Esmon, N. L., W. G. Owen, and C. T. Esmon. 1982. Isolation of a membrane-bound cofactor for thrombin catalyzed activation of protein C. *J. Biol. Chem.* 257:859-864.